"The quest for biomarkers": Are we on the right technical track?

Proteomics - Clinical Applications

Volumn 6, Issue 1-2, 2012, Pages 22-41

  Boschetti, Egisto ^a   Chung, Maxey C M ^b   Righetti, Pier Giorgio ^a  

^a POLITECNICO DI MILANO   (Italy)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biomarkers; Enrichment; Mass spectrometry; Protein fractionation; Subtraction

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER;

ACCURACY; CELL CULTURE; ENRICHMENT CULTURE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; ISOTOPE LABELING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEOMICS; REDUCTION KINETICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; VALIDATION PROCESS;

ANTIBODIES; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; ISOTOPE LABELING; PROTEIN ARRAY ANALYSIS; PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84858975768     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100039     Document Type: Review

References (139)

1. Kulasingam, V., Diamandis, E. P., Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5, 588-599.
2. Mitchell, P., Proteomics retrenches. Nat. Biotechnol. 2010, 28, 665-670.
3. Seyhan, A. A., Biomarkers in drug discovery and development. Eur. Biochem. Rev. 2010, 5, 19-25.
4. Di Girolamo, F., Boschetti, E., Chung, M. C. M., Guadagni, F., Righetti, P. G., ''Proteomineering'' or not? The debate on biomarkers discovery in sera continues. Electrophoresis 2011, 32, 589-594.
5. Brewis, I. A., Brennan, P., Proteomics technologies for the global identification and quantification of proteins. Adv. Protein Chem. Struct. Biol. 2010, 80, 1-44.
6. Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y. et al., Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002, 2, 76-84.
7. Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P. et al., Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 2003, 9, 2904-2911.
8. Mor, G., Visintin, I., Lai, Y., Zhao, H. et al., Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. 2005, 102, 7677-7682.
9. Zhang, Z., Bast, R. C., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
10. Moore, L. E., Fung, E. T., McGuire, M., Rabkin, C. C. et al., Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1641-1646.
11. Ahmed, A. S., Dew, T., Lawton, F. G., Papadopoulos, A. J. et al., M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur. J. Gynaecol. Oncol. 2007, 28, 83-88.
12. Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K. et al., Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5, 4589-4596.
13. Yan, X. D., Pan, L. Y., Yuan, Y., Lang, J. H. et al., Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J. Proteome Res. 2007, 6, 772-780.
14. Petri, A. L., Simonsen, A. H., Høgdall, E., Christensen, I. J. et al., Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics Clin. Appl. 2010, 4, 304-314.
15. Ramirez, A. B., Loch, C. M., Zhang, Y., Liu, Y. et al., Use of a single-chain antibody library for ovarian cancer biomarker discovery. Mol. Cell. Proteomics 2010, 9, 1449-1460.
16. Chow, S. N., Chen, R. J., Chen, C. H., Chang, T. C., Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology. Eur. J. Gynaecol. Oncol. 2010, 31, 55-62.
17. Oikonomopoulou, K., Batruch, I., Smith, C. R., Soosaipillai, A., Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. Biol. Chem. 2010, 391, 381-390.
18. Abbott, K. L., Lim, J. M., Wells, L., Benigno, B. B. et al., Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics 2010, 10, 470-481.
19. Andersen, J. D., Boylan, K. L., Xue, F. S., Anderson, L. B. et al., Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 2010, 31, 599-610.
20. Drabovich, A. P., Diamandis, E. P., Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. J. Proteome Res. 2010, 9, 1236-1245.
21. Husseinzadeh, N., Status of tumor markers in epithelial ovarian cancer has there been any progress? Gynecol. Oncol. 2011, 120, 152-157.
22. Leger, T., Lavigne, D., Le Caër, J. P., Guerrier, L. et al., Solid-phase hexapeptide ligand libraries open up new perspectives in the discovery 2 of biomarkers in human plasma. Clin. Chim. Acta 2011, 412, 740-747.
23. Fung, E. T., A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem. 2010, 56, 327-329.
24. Shaw, J. L., Smith, C. R., Diamandis, E. P., Proteomic analysis of human cervico-vaginal fluid. J. Proteome Res. 2007, 6, 2859-2865.
25. Ambatipudi, K. S., Lu, B., Hagen, F. K., Melvin, J. E. et al., Quantitative analysis of age specific variation in the abundance of human female parotid salivary proteins. J. Proteome Res. 2009, 8, 5093-5102.
26. Fortis, F., Guerrier, L., Girot, P., Fasoli, E. et al., A pI-based protein fractionation method using solid-state buffers. J. Proteomics 2008, 71, 379-389.
27. Riaz, S., Alam, S. S., Akhtar, M. W., Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J. Pharm. Biomed. Anal. 2010, 51, 1103-1107.
28. Smith, S. D., She, Y. M., Roberts, E. A., Sarkar, B., Using immobilized metal affinity chromatography, two-dimensional electrophoresis and mass spectrometry to identify hepatocellular proteins with copper-binding ability. J. Proteome Res. 2004, 3, 834-840.
29. Chaga, G. S., Twenty-five years of immobilized metal ion affinity chromatography: past, present and future. J. Biochem. Biophys. Meth. 2001, 49, 313-334.
30. Dursun, E., Monari, E., Cuoghi, A., Bergamini, S. et al., Proteomic profiling during atherosclerosis progression using SELDI-TOF-MS: effect of darbepoetin treatment. Acta Histochem. 2010, 112, 432-443.
31. Tang, H. Y., Speicher, D. W., Complex proteome prefractionation using microscale solution isoelectrofocusing. Expert Rev. Proteomics 2005, 2, 295-306.
32. Foucher, A. L., Craft, D. R., Gelfand, C. A., Application of free flow electrophoresis to the analysis of the urine proteome. Meth. Mol. Biol. 2010, 641, 27-45.
33. Pernemalm, M., Lewensohn, R., Lehtiö, J., Affinity prefractionation for MS-based plasma. Proteomics 2009, 9, 1420-1427.
34. Callesen, A. K., Madsen, J. S., Vach, W., Kruse, Y. A. et al., Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool? Proteomics 2009, 9, 1428-1441.
35. Sparbier, K., Asperger, A., Resemann, A., Kessler, I. et al., Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDITOF/TOF analysis with automated glycopeptide detection. J. Biomol. Technol. 2007, 18, 252-258.
36. Dayarathna, M. K., Hancock, W. S., Hincapie, M., A two step fractionation approach for plasma proteomics using immunodepletion of abundant proteins and multi-lectin affinity chromatography: Application to the analysis of obesity, diabetes, and hypertension diseases. J. Sep. Sci. 2008, 31, 1156-1166.
37. Dai, Z., Zhou, J., Qiu, S. J., Liu, Y. K. et al., Lectin-based glycoproteomics to explore and analyze hepatocellular carcinoma-related glycoprotein markers. Electrophoresis 2009, 30, 2957-2966.
38. Haab, B. B., Porter, A., Yue, T., Li, L. et al., Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann. Surg. 2010, 251, 937-945.
39. Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R. et al., Protein carbonylation in human diseases. Trends Mol. Med. 2003, 9, 169-176.
40. Jonasson, T., Ohlin, A. K., Gottsater, A., Hultberg, B. et al., Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease - a prospective randomized study of vitamin supplementation. Clin. Chem. Lab. Med. 2005, 43, 628-634.
41. Shi, Q., Gibson, G. E., Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007, 21, 276-291.
42. Yang, F., Yin, Y., Wang, F., Zhang, L. et al., An altered pattern of liver apolipoprotein A-I isoforms is implicated in male chronic hepatitis B progression. J. Proteome Res. 2010, 9, 134-143.
43. Andersen, J. N., Sathyanarayanan, S., Di Bacco, A., Chi, A. et al., Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl. Med. 2010, 2, 43-55.
44. Lei, T., He, Q. Y., Wang, Y. L., Si, L. S. et al., Heparin chromatography to deplete high-abundance proteins for serum proteomics. Clin. Chim. Acta 2008, 388, 173-178.
45. Rho, J. H., Qin, S., Wang, J. Y., Roehrl, M. H., Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J. Proteome Res. 2008, 7, 2959-2972.
46. Karlsson, K., Cairns, N., Lubec, G., Fountoulakis, M., Enrichment of human brain proteins by heparin chromatography. Electrophoresis 1999, 20, 2970-2976.
47. Cussenot, O., Growth factors and prostatic tumors. Ann. Endocrinol. 1997, 58, 370-380.
48. Ahmed, N., Barker, G., Oliva, K., Garfin, D. et al., An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 2003, 3, 1980-1987.
49. Govorukhina, N. I., Reijmers, T. H., Nyangoma, S. O., van der Zee, A. G. et al., Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. J. Chromatogr. A 2006, 1120, 142-150.
50. Fu, Q., Garnham, C. P., Elliott, S. T., Bovenkamp, D. E. et al., A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis. Proteomics 2005, 5, 2656-2664.
51. Steel, L. F., Trotter, M. G., Nakajima, P. B., Mattu, T. S. et al., Efficient and specific removal of albumin from human serum samples. Mol. Cell. Proteomics 2003, 2, 262-270.
52. Pieper, R., Su, Q., Gatlin, C. L., Huang, S. T. et al., Multicomponent immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003, 3, 422-432.
53. Hinerfeld, D., Innamorati, D., Pirro, J., Tam, S. W., Serum/plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple Mammalian species. J. Biomol. Tech. 2004, 15, 184-190.
54. Huang, L., Harvie, G., Feitelson, J. S., Gramatikoff, K. et al., Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 2005, 5, 3314-3328.
55. Schuchard, M. D., Melm, C. D., Crawford, A. S., Chapman, H. A. et al., Immunoaffinity depletion of 20 high-abundance human plasma proteins. Removal of approximately 97% of total plasma protein improves identification of low abundance proteins. Origins 2005, 21, 17-23.
56. Lin, B., White, J. T., Wu, J., Lele, S. et al., Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin. Appl. 2009, 3, 853-861.
57. Shen, Y., Kim, J., Strittmatter, E. F., Jacobs, J. M. et al., Characterization of the human blood plasma proteome. Proteomics 2005, 5, 4034-4045.
58. Seam, N., Gonzales, D. A., Kern, S. J., Hortin, G. L. et al., Quality control of serum albumin depletion for proteomic analysis. Clin. Chem. 2007, 53, 1915-1920.
59. Tu, C., Rudnick, P. A., Martinez, M. Y., Cheek, K. L. et al., Depletion of abundant plasma proteins and limitations of plasma proteomics. J. Proteome Res. 2010, 9, 4982-4991.
60. Byrne, J. C., Downes, M. R., O'Donoghue, N., O'Keane, C. et al., 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J. Proteome Res. 2009, 8, 942-957.
61. Afkarian, M., Bhasin, M., Dillon, S. T., Guerrero,M. C. et al., Optimizing a proteomics platform for urine biomarker discovery. Mol. Cell. Proteomics 2010, 9, 2195-2204.
62. Juhasz, P., Lynch, M., Sethuraman, M., Campbell, J. et al., Semi-targeted plasma proteomics discovery workflow utilizing two-stage protein depletion and off-line LC-MALDI MS/MS. J. Proteome Res. 2011, 10, 34-45.
63. Righetti, P. G., Boschetti, E., Kravchuk, A., Fasoli, E., The proteome buccaneers: how to unearth your treasure chest via combinatorial peptide ligand libraries. Expert Rev. Proteomics 2010, 7, 373-385.
64. Høgdall, E., Fung, E. T., Christensen, I. J., Yip, C. et al., Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin. Appl. 2010, 4, 940-952.
65. Au, J. S., Cho, W. C., Yip, T. T., Yip, C. et al., Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed. Pharmacother. 2007, 61, 570-577.
66. Sihlbom, C., Kanmert, I., Bahr, H., Davidsson, P., Evaluation of the combination of bead technology with SELDITOF- MS and 2-D DIGE for detection of plasma proteins. J. Proteome Res. 2008, 7, 4191-4198.
67. Marrocco, C., Rinalducci, S., Mohamadkhani, A., D'Amici, G. M. et al., Plasma gelsolin protein: a candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach. Blood Transfus. 2010, 8, 105-512.
68. Ernoult, E., Bourreau, A., Gamelin, E., Guette, C., A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J. Biomed. Biotechnol. 2010, 2010, 927917.
69. Petri, L. A., Simonsen, A. H., Yip, T. T., Hogdall, E. et al., Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet. Gynecol. 2009, 88, 18-26.
70. Fakelman, F., Felix, K., Buchler, M. W., Werner, J., New pre-analytical approach for the deep proteome analysis of sera from pancreatitis and pancreas cancer patients. Arch. Physiol. Biochem. 2010, 116, 208-217.
71. Li, L., Sun, C. J., Feeby, S., Yee, D. et al., Protein sample treatment with peptide ligand library: coverage and consistency. J. Prot. Bioinform. 2009, 2, 485-494.
72. Mouton-Barbosa, E., Roux-Dalvai, F., Bouyssié, D., Berger, F. et al., In-depth exploration of cerebrospinal fluid combining peptide ligand library treatment and label-free protein quantification. Mol. Cell. Proteomics 2010, 9, 1006-1021.
73. O'Farrell, P. H., High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 1975, 250, 4007-4021.
74. Bjellqvist, B., Ek, K., Righetti, P. G., Gianazza, E. et al., Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J. Biochem. Biophys. Meth. 1982, 6, 317-339.
75. Rabilloud, T., Adessi, C., Giraudel, A., Lunardi, J., Improvement of the solubilization of proteins in twodimensional electrophoresis with immobilized pH gradients. Electrophoresis 1997, 18, 307-316.
76. Lilley, K. S., Friedman, D. B., All about DIGE: Quantification technology for differential-display 2D-gel proteomics. Expert Rev. Proteomics 2004, 1, 401-409.
77. Unlu, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18, 2071-2077.
78. Alban, A., David, S. O., Bjorkesten, L., Andersson, C. et al., A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36-44.
79. Netea-Maier, R. T., Hunsucker, S. W., Hoevenaars, B. M., Helmke, S. M. et al., Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res. 2008, 68, 1572-1580.
80. Ma, Y., Peng, J., Huang, L., Liu, W. et al., Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis 2009, 30, 2591-2599.
81. Taneja, S., Sen, S., Gupta, V. K., Aggarwal, R. et al., Plasma and urine biomarkers in acute viral hepatitis E. Proteome Sci. 2009, 27, 7-39.
82. Zhang, L., Xiao, H., Karlan, S., Zhou, H. et al., Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 2010, 5, e15573.
83. Tian, M., Cui, Y. Z., Song, G. H., Zong, M. J. et al., Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8, 241-248.
84. Liu, S., Sun, M. Z., Tang, J. W., Wang, Z. et al., Highperformance liquid chromatography/nano-electrospray ionization tandem mass spectrometry, two-dimensional difference in-gel electrophoresis and gene microarray identification of lymphatic metastasis-associated biomarkers. Rapid Commun. Mass Spectrom. 2008, 22, 3172-3178.
85. Gandhi, K. S., McKay, F. C., Diefenbach, E., Crossett, B. et al., Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis. PLos One 2010, 5, e10484.
86. Jourdain, S., Bulman, A., Dalmasso, E., The lucid proteomics system for top-down biomarker research. Arch. Physiol. Biochem. 2010, 116, 158-162.
87. Al-Ruwaili, J. A., Larkin, S. E., Zeidan, B. A., Taylor, M. G. et al., Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis. Cancer Genomics Proteomics 2010, 7, 93-103.
88. Sreseli, R. T., Binder, H., Kuhn, M., Dige, l. W. et al., Identification of a 17-protein signature in the serum of lung cancer patients. Oncol. Rep. 2010, 24, 263-270.
89. Li, J., Zhao, J., Yu, X., Lange, J. et al., Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin. Cancer Res. 2005, 11, 8312-8820.
90. Lebrecht, A., Boehm, D., Schmidt, M., Koelbl, H. et al., Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry to detect breast cancer markers in tears and serum. Cancer Genomics Proteomics 2009, 6, 75-83.
91. Simonsen, A. H., McGuire, J., Podust, V. N., Davies, H. et al., Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 2008, 29, 961-968.
92. He, H., Sun, G., Ping, F., Laser-capture microdissection and protein extraction for protein fingerprint of OSCC and OLK. Artif. Cells Blood Substit. Immobil. Biotechnol. 2009, 37, 208-213.
93. Beyer, M., Block, I., König, K., Nesterov, A. et al., A novel combinatorial approach to high-density peptide arrays. Methods Mol. Biol. 2009, 570, 309-316.
94. Patwa, T., Li, C., Simeone, D. M., Lubman, D. M., Glycoprotein analysis using protein microarrays and mass spectrometry. Mass Spectrom. Rev. 2010, 29, 830-844.
95. Narimatsu, H., Sawaki, H., Kuno, A., Kaji, H. et al., A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J. 2010, 277, 95-105.
96. Brody, E. N., Gold, L., Lawn, R. M., Walker, J. J. et al., Highcontent affinity-based proteomics: unlocking protein biomarker discovery. Expert Rev. Mol. Diagn. 2010, 10, 1013-1022.
97. Zhang, Y., Campbell, C., Li, Q., Gildersleeve, J. C., Multidimensional glycan arrays for enhanced antibody profiling. Mol. Biosyst. 2010, 6, 1583-1591.
98. Wingren, C., Borrebaeck, C. A., Antibody-based microarrays. Methods Mol. Biol. 2009, 509, 57-84.
99. Berglund, L., Bjorling, E., Oksvold, P., Fagerberg, L. et al., A Genecentric human protein atlas for expression profiles based on antibodies. Mol. Cell. Proteomics 2008, 7, 2019-2027.
100. Kiernan, U. A., Nedelkov, D., Nelson, R. W., Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J. Proteome Res. 2006, 5, 2928-2934.
101. Thongboonkerd, V., Recent progress in urinary proteomics. Proteomics Clin. Appl. 2007, 1, 780-791.
102. Kim, M. K., Oh, Y. H., Kang, J., Kim, Y. P. et al., Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray. Proteomics 2009, 9, 5544-5552.
103. Breitling, F., Nesterov, A., Stadler, V., Felgenhauer, T. et al., High-density peptide arrays. Mol. Biosyst. 2009, 5, 224-234.
104. Kijanka, G., Murphy, D., Protein arrays as tools for serum autoantibody marker discovery in cancer. J. Proteomics 2009, 72, 936-944.
105. Chatterjee, M., Wojciechowski, J., Tainsky, M. A., Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput. Methods Mol. Biol. 2009, 520, 21-38.
106. Reddy, M. M., Wilson, R., Wilson, J., Connell, S. et al., Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 2011, 144, 132-142.
107. Mueller, C., Liotta, L. A., Espina, V., Reverse phase protein microarrays advance to use in clinical trials. Mol. Oncol. 2010, 4, 461-481.
108. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
109. Ong, S. E., Foster, L. J., Mann, M., Mass spectrometricbased approaches in quantitative proteomics. Methods 2003, 29, 124-130.
110. Geiger, T., Wisniewski, J. R., Cox, J., Zanivan, S. et al., Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat. Protoc. 2011, 6, 147-157.
111. Wolters, D. A., Washburn, M. P., Yates, J. R., Wolters, D. et al., An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 2001, 73, 5683-5690.
112. Wang, W., Guo, T., Rudnick, P. A., Song, T. et al., Membrane proteome analysis of microdissected ovarian tumor tissues using capillary isoelectric focusing/reversedphase liquid chromatography-tandem MS. Anal. Chem. 2007, 79, 1002-1009.
113. Waller, L. N., Shores, K., Knapp, D. R., Shotgun proteomic analysis of cerebrospinal fluid using off-gel electrophoresis as the first-dimension separation. J. Proteome Res. 2008, 7, 4577-4584.
114. Davis, M. T., Spahr, C. S., McGinley, M. D., Robinson, J. H. et al., Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. II. Limitations of complex mixture analyses. Proteomics 2001, 1, 108-117.
115. Niu, H. T., Zhang, Y. B., Jiang, H. P., Cheng, B. et al., Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urothelium. Urol. Oncol. 2009, 27, 400-406.
116. Hu, S., Arellano, M., Boontheung, P., Wang, J. et al., Salivary proteomics for oral cancer biomarker discovery. Clin. Cancer Res. 2008, 14, 6246-6252.
117. Zhi, W., Purohit, S., Carey, C., Wang, M. et al., Proteomic technologies for the discovery of type 1 diabetes biomarkers. J. Diabetes Sci. Technol. 2010, 4, 993-1002.
118. Parker, C. E., Pearson, T. W., Anderson, N. L., Borchers, C. H., Mass-spectrometry-based clinical proteomics - A review and prospective. Analyst 2010, 135, 1830-1838.
119. Jiang, J., Parker, C. E., Hoadley, K. A., Perou, C. M. et al., Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics Clin. Appl. 2007, 1, 1651-1659.
120. Parker, C. E., Smith, D., Suckau, D., Borchers, C. H., Advanced imaging in biology and medicine, Sensen, C. W., Hallgrímsson, B. (Eds.). Springer, Berlin, Heidelberg 2009, pp. 131-146.
121. Szabados, F., Woloszyn, J., Richter, C., Kaase, M., Gatermann, S., Identification of molecularly defined Staphylococcus aureus strains using matrixassisted laser desorption/ionization time of flight mass spectrometry and the Biotyper 2.0 database. J. Med. Microbiol. 2010, 59, 787-790.
122. Ferreira, L., Sá nchez-Juanes, F., García-Fraile, P., Rivas, R. et al., MALDI-TOF Mass spectrometry is a fast and reliable platform for identification and ecological studies of species from family Rhizobiaceae. PLoS One 2011, 6, e20223.
123. Plavina, T., Wakshull, E., Hancock, W. S., Hincapie, M., Combination of abundant protein depletion and multilectin affinity chromatography (M-LAC) for plasma protein biomarker discovery. J. Proteome Res. 2007, 6, 662-671.
124. Thulasiraman, V., Lin, S., Gheorghiu, L., Lathrop, J. et al., Reduction of concentration difference of proteins from biological liquids using combinatorial ligands. Electrophoresis 2005, 26, 3561-3571.
125. Boschetti, E., Righetti, P. G., Mixed-bed chromatography: principles and applications. J. Chromatogr. 2011, 89, 827-835.
126. Kullolli, M., Hancock, W. S., Hincapie, M., Preparation of a high-performance multi-lectin affinity chromatography (HP-M-LAC) adsorbent for the analysis of human plasma glycoproteins. J. Sep. Sci. 2008, 31, 2733-2739.
127. Grønborg, M., Kristiansen, T. Z., Stensballe, A., Andersen, J. S. et al., A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein Frigg as a protein kinase A substrate. Mol. Cell. Proteomics 2002, 1, 517-527.
128. Madian, A. G., Regnier, F. E., Proteomic identification of carbonylated proteins and their oxidation sites. J. Proteome Res. 2010, 9, 3766-3780.
129. Fortis, F., Guerrier, G., Areces, L., Antonioli, P. et al., A new approach for the amplification, and identification of protein impurities from purified biopharmaceuticals using combinatorial solid phase ligand libraries. J. Proteome Res. 2006, 5, 2577-2585.
130. Fonslow, B. R., Carvalho, P. C., Academia, K., Freeby, S. et al., Improvements in proteomic metrics of low abundance proteins through proteome equalization using ProteoMiner prior to MudPIT. J. Proteome Res. 2011, 10, 3690-3700.
131. Loo, D., Jones, A., Hill, M. M., Lectin magnetic bead array for biomarker discovery. J. Proteome Res. 2010, 9, 5496-5500.
132. Fröbel, J., Hartwig, S., PaXlack, W., Eckel, J. et al., ProteoMinerTM and SELDI-TOF-MS: a robust and highly reproducible combination for biomarker discovery from whole blood serum. Arch. Physiol. Biochem. 2010, 116, 174-180.
133. Siegmund, R., Kiehntopf, M., Deufel, T., Evaluation of two different albumin depletion strategies for improved analysis of human CSF by SELDI-TOF-MS. Clin. Biochem. 2009, 42, 1136-1143.
134. Monari, E., Casali, C., Coughi, A., Nesci, J. et al., Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers. Proteome Sci. 2011, 9, 55-65.
135. Roux-Dalvai, F., Gonzalez de Peredo, A., Simó, C., Guerrier, L. et al., Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced spectrometry. Mol. Cell. Proteomics 2008, 7, 2254-2269.
136. Qian, W. J., Kaleta, D. T., Petritis, B. O., Jiang, H. et al., Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol. Cell. Proteomics 2008, 7, 1963-1973.
137. Veenstra, T. D., Global and targeted quantitative proteomics for biomarker discovery. J. Chromatogr. B 2007, 847, 3-11.
138. Wang, D., Hincapie, M., Guergova-Kuras, M., Kadas, J. et al., Antigen identification and characterization of lung cancer specific monoclonal antibodies produced by mAb proteomics. J. Proteome Res. 2010, 9, 1834-1842.
139. Sun, J., Zhao, Z., A comparative study of cancer proteins in the human protein-protein interaction network. BMC Genomics 2010, 11, s5.